Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review

Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which had primarily positive conclusions, were investigated. Results from secondary endpoints in positive Study 302 were significant and these endpoints provid...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickson, Samuel P., Hennessey, Sean, Nicodemus Johnson, Jessie, Knowlton, Newman, Hendrix, Suzanne B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207692/
https://www.ncbi.nlm.nih.gov/pubmed/37226162
http://dx.doi.org/10.1186/s13195-023-01238-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207692/
https://www.ncbi.nlm.nih.gov/pubmed/37226162
http://dx.doi.org/10.1186/s13195-023-01238-1

Ejemplares similares